The present disclosure provides methods and formulations for reducing ammonia and carbon dioxide emissions from a bovine using lubabegron, or a physiologically acceptable salt thereof. The present disclosure also provides bovine feed additives and bovine feed compositions.

The present disclosure provides methods and formulations for reducing ammonia and carbon dioxide emissions from a bovine using lubabegron, or a physiologically acceptable salt thereof. The present disclosure also provides bovine feed additives and bovine feed compositions.

The present invention relates to a use of agar-derived oligosaccharides for inhibiting the growth of Staphylococcus. More specifically, the present invention provides, as a material for medicine, food, cosmetics and the like, a use of agar-derived agarooligosaccharides, agarobiose or AHG, which have an effect of inhibiting the growth of Staphylococcus or killing the same.

The present invention relates to a use of agar-derived oligosaccharides for inhibiting the growth of Staphylococcus. More specifically, the present invention provides, as a material for medicine, food, cosmetics and the like, a use of agar-derived agarooligosaccharides, agarobiose or AHG, which have an effect of inhibiting the growth of Staphylococcus or killing the same.

A peptide according to an embodiment of the present in which, in the amino acid sequence of SEQ ID NO: 1, (i) 2nd and 4th amino acids are each substituted with tryptophan (W); (ii) 2nd, 4th, 11st and 13rd amino acids are each substituted with tryptophan; and (iii) 2nd, 4th, 19th, 20th, 22nd, 23rd, 26th and 27th amino acids are each substituted with tryptophan. The peptide can be usefully applied as an active ingredient for antibiotics, cosmetic compositions, food additives, feed additives, biological pesticides and quasi-drugs.

The present invention relates to a use of a compound comprising a multivalent sialyloligosaccharide residue, an optical isomer thereof or a pharmaceutically acceptable salt thereof, and a composition comprising the same as an active ingredient for preventing or treating viral infectious diseases. The present invention shows high hemagglutination inhibitory activity and virus neutralizing activity so as to have excellent antiviral activity, thereby being effectively usable as a composition for preventing or treating viral infectious diseases.

Pelleted compositions of legume forages including Arachis glabrata and/or Crotalaria juncea L. are disclosed. Arachis glabrata and/or Crotalaria juncea L. can be pelleted alone or in combination with other forages such as alfalfa, clover, and lespedeza. The pellets can be of various shapes and sizes, for example about 6.3-10.0 mm diameter and/or 13-25 mm length cylinders. The density of per unit of pellets can be about 960-1120 kg/m.sup.3. Also disclosed are methods of using the pelleted compositions. Such methods involve improving weight gain or growth of animals by causing the animal to ingest the disclosed compositions. Methods for preventing or treating gastrointestinal nematode infections in animals are also provided. Animals that may benefit from the disclosed compositions include, but are not limited to equidae, ruminants, and zoo animals, for example, horses, cattle (both beef and dairy), sheep, goats, pigs, rabbits, and ostriches.

A method of controlling a tight junction between epithelial cells of an animal comprises providing the animal with a feed containing polyphenols in an amount effective to increase transmembrane protein levels between the epithelial cells thereby minimizing passage of macromolecules between the epithelial cells of the animal

A method of controlling a tight junction between epithelial cells of an animal comprises providing the animal with a feed containing polyphenols in an amount effective to increase transmembrane protein levels between the epithelial cells thereby minimizing passage of macromolecules between the epithelial cells of the animal

This disclosure provides materials and methods for reducing production of virulence factors in C. perfringens and or other pathogenic clostridia with related Agr-like QS systems using compounds that interfere with the Agr-like quorum sensing (QS) system. For example, Agr-like QS system inhibitors based on peptidomimetic compounds of the Agr-like QS system signaling peptide (SP) or the SP receptor of C. perfringens, and methods of using the Agr-like QS system inhibitors to prevent, treat, or ameliorate a disease associated with C. perfringens infection are provided.